Market Expansion

Business

Apple Reportedly Shifts 2026 iPhone Strategy: Premium Models Take Priority, Standard Edition Faces Delay

Apple is reportedly planning to prioritize the launch of its three highest-tier iPhone models in 2026, while delaying the rollout of a new standard edition, according to a Nikkei Asia report citing sources familiar with the matter. The move signals a strategic pivot towards the premium segment amid ongoing supply chain considerations.

Jan 30, 2026

Business

Capital Metals Eyes Profitability by 2028 as Analysts Forecast Aggressive Turnaround

London-listed mineral sands explorer Capital Metals (LON: CMET) is projected to reach breakeven within two years, with analysts forecasting a first profit in 2028. The debt-free company's path hinges on achieving a steep annual growth rate amid its investment phase in UK and Sri Lankan projects.

Jan 30, 2026

Business

Motorpoint Group's Declining Returns on Capital Raise Concerns Among Investors

Motorpoint Group, the UK's largest independent car retailer, is showing signs of strain as its return on capital employed (ROCE) has fallen significantly over the past five years. While still above the industry average, the downward trend, coupled with rising current liabilities, suggests challenges ahead for the London-listed firm.

Jan 30, 2026

Business

Analysts Flag LSL Property Services as Undervalued, Shares Trading at a Steep Discount

A new financial analysis suggests shares of UK property services group LSL could be trading at a significant discount to their estimated intrinsic value, presenting a potential opportunity for investors.

Jan 30, 2026

Business

Karman Holdings (KRMN) Soars on Analyst Optimism: A Defense Tech Darling in the Making?

Karman Holdings (NYSE: KRMN) is capturing Wall Street's attention as a series of bullish analyst calls, including a significant price target hike from KeyBanc, fuel its ascent. The stock's rally is tied to sustained momentum in the aerospace and defense sector, though some advise caution after its rapid gains.

Jan 30, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target

Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.

Jan 30, 2026

Business

Analysts Trim Targets on Duolingo Amid Questions Over User Growth Sustainability

DA Davidson joins Morgan Stanley in lowering price targets for language-learning app Duolingo, citing data suggesting daily active user growth may fall short of expectations despite a strong start to the year.

Jan 30, 2026

Business

Analysts Bullish on Riot Platforms After Strategic AMD Data Center Deal

Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

Business

TD Cowen Stands By Alphatec (ATEC) With Buy Rating, Sees $20 Target Amid Coverage Shift

Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.

Jan 30, 2026

Business

Bank of America Bullish on Apellis, Upgrades to 'Buy' on Strong Drug Launch and Kidney Disease Prospects

Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.

Jan 30, 2026

Business

NextPower Soars on Strong Earnings, Lands Major Saudi Deal as Analyst Target Jumps

NextPower Inc. sees its price target raised by TD Cowen following a robust third-quarter earnings beat and a landmark joint venture in Saudi Arabia, signaling growing confidence in the solar technology firm's trajectory.

Jan 30, 2026

Business

Analysts Bullish on Core Scientific's AI Pivot, Price Targets Raised

Wall Street firms Keefe Bruyette and BTIG have raised price targets on Core Scientific, citing the company's strategic shift from Bitcoin mining to high-performance computing infrastructure for AI as a key driver for future growth.

Jan 30, 2026

Business

Barclays Taps Astera Labs as Key AI Infrastructure Bet for 2026, Sees Quality Firms Leading the Pack

Barclays raises Astera Labs' price target to $165, naming it a top pick for AI integration plays in its 2026 semiconductor outlook, while contrasting analyst views highlight the evolving debate on AI's infrastructure demands.

Jan 30, 2026

Business

Hutchison Port Holdings Trust Sees Efficiency Gains, But Can Its ROCE Momentum Hold?

The Singapore-listed port operator has significantly improved its capital efficiency over five years, rewarding shareholders. Analysts are now weighing whether this trend is sustainable for long-term growth.

Jan 30, 2026

Business

Analysts See Deep Value in Corero Network Security, Suggesting Shares Could Be Undervalued by Over 40%

A new discounted cash flow analysis indicates Corero Network Security plc (LON:CNS) may be significantly undervalued at current trading levels, presenting a potential opportunity for investors in the cybersecurity sector.

Jan 30, 2026

Business

Apple Feels the Pinch: Global Memory Chip Shortage Begins to Bite Tech Giant

Despite record iPhone demand, Apple CEO Tim Cook warns that soaring memory chip costs are set to squeeze margins, highlighting a supply crisis gripping the entire tech industry.

Jan 30, 2026

Business

Australia Vows to Press Ahead with Critical Minerals Strategy Despite U.S. Policy Shift

Australia reaffirms its commitment to building resilient critical mineral supply chains and a strategic reserve, undeterred by the U.S. stepping back from plans to guarantee minimum prices for such projects.

Jan 30, 2026

Business

Bango's Turnaround: From Losses to Profitability as Capital Efficiency Rises

The UK-based payments technology firm Bango (LON:BGO) is showing early signs of a financial transformation, breaking into profitability and increasing its capital deployment. While its return on capital remains below the software industry average, the underlying trend suggests a company in the midst of a strategic pivot.

Jan 30, 2026